Reshaping the Treatment Landscape in the Department of Veteran Affairs: Immunotherapy in Non-Melanoma Skin Cancer
The Role of Immunotherapy in Patients with BCC
Post-Test/Evaluation
Questions marked with a
*
are required
36%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Which of the following are not true statements about vismodegib?
Vismodegib is indicated for metastatic basal cell carcinoma.
Vismodegib is indicated for locally advanced basal cell carcinoma that has recurred following surgery.
Vismodegib is indicated for locally advanced basal cell carcinoma in those who are candidates for surgery and/or radiation therapy.
Vismodegib has no contraindications.
Which of the following are not true statements about hedgehog pathway inhibitors (HHI)?
HHI side effects are universal and often severe
HHI side effects are often life-threatening
Alternatives to daily dosing are often used with HHIs.
High rates of discontinuations in clinical trials were due to muscle pain/cramping, loss of taste, weight loss, and extensive hair loss.
What is your job role?
Dermatologist
Medical oncologist
Radiation oncologist
Mohs surgeon
Other surgical oncologist
Pathologist
Physician Assistant
Internal medicine
Primary Care
Nurse Practitioner
Nurse
Pharmacist
Other
What is your type of practice?
Hospital
Community/Private
SNF/Nursing Home
Academic
HMO/MCO
Other
How many years have you been in practice?
Less than 5
5 to 9
10 to 15
More than 15
N/A
Please estimate the number of patients with or at risk for non-melanoma skin cancer that you provide for
weekly:
Fewer than 5
5 to 10
11 to 15
16 to 20
21 to 30
31 to 50
N/A
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close